This website uses Google Analytics cookies and other cookies to collect anonymous data for statistical purposes to improve our customer service. If you continue browsing, we consider that you agree to its use of cookies policy.


This medicinal product is for diagnostic use only

PYLCLARITM is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

Primary staging of patients with high-risk PCa prior to initial curative therapy.
To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.

Detailed recommendations for the use of this product can be found in the Summary of Product Characteristics (SmPC).

*The Marketing Authorization has been granted for PYLCLARITM in all EU members. PYLCLARITM might not be commercially available yet in your country

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See SmPC, section 4.8 for how to report adverse reactions.

Important notice

The information on this page is intended for use by healthcare providers only. By continuing, you automatically confirm that you are a professional healthcare provider in a European country.